Welcome to our dedicated page for Grace Therapeutics SEC filings (Ticker: GRCE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Grace Therapeutics, Inc. filings document material events, operating updates and governance matters for a late-stage biopharma company advancing GTx-104. Form 8-K disclosures cover quarterly results, corporate presentations, the GTx-104 New Drug Application, the FDA Complete Response Letter, and the chemistry, manufacturing and controls and non-clinical subjects cited in that regulatory correspondence.
The filing record also includes disclosures on patent protection for “Nimodipine Parenteral Administration,” exercises and expirations of common warrants issued in private placements, exhibit-based press releases, and amendments to executive letter agreements and compensation arrangements.
Grace Therapeutics, Inc. updated its executive employment arrangements by entering into amendments to existing letter agreements with its CEO and four other executive officers. If an executive is terminated by the company without Cause, and there is no Change in Control, the executive will receive accrued obligations plus continued base salary and COBRA benefits for six months, or twelve months in the case of the CEO. Unvested equity awards are forfeited in this scenario.
If an executive is terminated without Cause or resigns for Good Reason in connection with or within twelve months after a Change in Control, the executive will receive accrued obligations plus a cash payment equal to six months (eighteen months for the CEO) of base salary and target bonus, as well as COBRA premiums for the same period. In this Change in Control context, all unvested equity awards held by the executive will fully vest and become exercisable.
Grace Therapeutics, Inc. director Vimal Kavuru reported a grant of stock options on January 8, 2026. He received a stock option to buy 10,000 shares of Grace Therapeutics common stock at an exercise price of $3.8 per share, held in direct ownership. Following this grant, he beneficially owns options for 10,000 shares.
According to the vesting terms, 25% of the option vests on the grant date, and the remaining 75% vests in substantially equal monthly installments on the 30th day of each month until September 30, 2026, provided he continues to serve the company through each vesting date.
Grace Therapeutics, Inc. director Kottayil George reported a grant of a stock option covering 10,000 shares of common stock of Grace Therapeutics. The option, with an exercise price of $3.8 per share, was awarded on January 8, 2026 and is held directly.
According to the vesting terms, 25% of the option vests on the grant date, and the remaining 75% vests in substantially equal monthly installments on the 30th day of each month until September 30, 2026, subject to George’s continued service on each vesting date.
Grace Therapeutics director Edward Neugeboren received a grant of stock options on January 8, 2026. The award is a stock option (right to buy) covering 10,000 shares of common stock at an exercise price of $3.8 per share, with no cost to receive the option itself.
According to the disclosure, 25% of the option vests on the grant date, and the remaining 75% vests in substantially equal monthly installments on the 30th day of each month until September 30, 2026, as long as Neugeboren continues in service. After this grant, he holds 10,000 derivative securities directly.
Grace Therapeutics director reports stock option grant. Director Brian A. Davis reported receiving a stock option to buy 10,000 shares of Grace Therapeutics, Inc. common stock on January 8, 2026 at an exercise price of $3.8 per share. The filing shows that 25% of the option vests on the grant date, with the remaining 75% vesting in substantially equal monthly installments on the 30th day of each month until September 30, 2026, subject to his continuous service. Following this grant, he beneficially owned 10,000 derivative securities directly.
Grace Therapeutics, Inc. filed Amendment No. 1 to its quarterly report to correct the number of common shares reported as outstanding on the cover page. The amended filing now states that 15,474,026 shares of common stock were outstanding as of November 13, 2025. The company confirms that no other changes were made to the original quarterly report, and no financial statements were updated. In line with amendment rules, the company included new certifications from its chief executive officer and principal financial officer as exhibits.
Grace Therapeutics (GRCE) furnished an 8-K noting it issued a press release with financial results for the three months ended September 30, 2025. The company also updated its corporate presentation, which includes its updated cash position as of October 31, 2025.
The press release and presentation are furnished as Exhibits 99.1 and 99.2. The company states these materials are furnished, not “filed,” under the Exchange Act.
Grace Therapeutics (GRCE) filed its quarterly report for the quarter ended September 30, 2025. The company reported a net loss of $0.9 million (basic and diluted loss per share of $0.06) for the quarter and a six‑month net loss of $4.3 million (loss per share of $0.27).
Cash and cash equivalents were $16.9 million as of September 30, 2025. Operating cash outflow totaled $4.9 million for the six months. Total liabilities were $3.8 million, with derivative warrant liabilities declining to $0.2 million from $1.1 million at March 31, 2025. Stockholders’ equity stood at $62.8 million. The company states existing cash is sufficient to sustain planned operations for at least 12 months from the statements’ issuance.
Development remains centered on GTx‑104 (IV nimodipine) for aneurysmal subarachnoid hemorrhage: the NDA was accepted with a PDUFA target date of April 23, 2026. Subsequent to quarter end, Grace received $4.0 million in gross proceeds from 2023 warrant exercises. Shares outstanding were 14,128,562 as of November 13, 2025.
Grace Therapeutics reported securing approximately $4.0 million in cash proceeds from recent exercises of common warrants originally issued in a September 2023 private placement.
The Company also disclosed that 1,190,927 of those common warrants have expired, as the 60th day after the U.S. Food and Drug Administration’s acceptance for review of the Company’s New Drug Application for GTx-104 has passed. GTx-104 is a clinical-stage, injectable formulation of nimodipine being developed for I.V. infusion to address unmet needs in aneurysmal subarachnoid hemorrhage.
Grace Therapeutics announced that the U.S. Patent and Trademark Office issued Patent No. 12,414,943, titled "Nimodipine Parenteral Administration." The method-of-use patent, published on September 16, 2025 and issued on September 18, 2025, covers the dosing regimen for intravenous administration of nimodipine used in the Phase 3 STRIVE-ON safety trial for GTx-104 and extends patent protection for GTx-104 to 2043. GTx-104 is described as a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to treat aneurysmal subarachnoid hemorrhage patients. The company attached a press release as Exhibit 99.1 to this Current Report.
Grace Therapeutics announced that the U.S. Patent and Trademark Office issued Patent No. 12,414,943, titled "Nimodipine Parenteral Administration." The method-of-use patent, published on September 16, 2025 and issued on September 18, 2025, covers the dosing regimen for intravenous administration of nimodipine used in the Phase 3 STRIVE-ON safety trial for GTx-104 and extends patent protection for GTx-104 to 2043. GTx-104 is described as a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to treat aneurysmal subarachnoid hemorrhage patients. The company attached a press release as Exhibit 99.1 to this Current Report.
Grace Therapeutics announced that the U.S. Patent and Trademark Office issued Patent No. 12,414,943, titled "Nimodipine Parenteral Administration." The method-of-use patent, published on September 16, 2025 and issued on September 18, 2025, covers the dosing regimen for intravenous administration of nimodipine used in the Phase 3 STRIVE-ON safety trial for GTx-104 and extends patent protection for GTx-104 to 2043. GTx-104 is described as a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to treat aneurysmal subarachnoid hemorrhage patients. The company attached a press release as Exhibit 99.1 to this Current Report.